This technology describes a dual-pathway targeting approach to effectively treat castration-resistant prostate cancers.
Treatment approaches for prostate cancer often include surgery and radiation combined with androgen deprivation therapy and medical castration. However, about one-third of men experience relapse despite these approaches, resulting in castration-resistant prostate cancer (CRPC). Currently, the only available treatment for CRPCs targets the androgen receptor, and many CRPC tumors can develop resistance to this treatment. Therefore, there is a pressing need for CRPC treatments capable of inhibiting tumor growth independently of the androgen receptor pathway.
This technology is an approach to overcome castration-resistant prostate cancer (CRPC) by inducing tumor cell death without targeting the androgen receptor. The treatment works by inducing ferroptosis, or cell death caused by loss of iron homeostasis, in prostate epithelial cells by targeting the signaling and metabolic pathways. This technology has the potential to overcome treatment-resistant CRPC.
This technology has been validated in vivo using mouse models.
Patent Pending
IR CU25059
Licensing Contact: Joan Martinez